Viviane Lucia Beraldo de Araujo

Mrs. Viviane Lucia Beraldo de Araujo

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
RFRenata De Carvalho Feitosa
Renata De Carvalho Feitosa
DGDanilo Costa Geraldes
Danilo Costa Geraldes
VAViviane Lucia Beraldo de Araujo
Viviane Lucia Beraldo de Araujo
Juliana Souza Ribeiro CostaJuliana Souza Ribeiro Costa
Juliana Souza Ribeiro Costa
LOLaura Oliveira-Nascimento
Laura Oliveira-Nascimento
Oral route maintains its predominance among the ones used for drug delivery, especially when medicines are self-administered. If the dosage form is solid, therapy gains in dose precision and drug stability. Yet, some active pharmaceutical substances do not present the required solubility, permeability or release profile for incorporation into traditional matrices. The combination of nanostructured drugs (NP) with these matrices is a new and little-explored alternative, which could bring several benefits. Therefore, this review focused on combined delivery systems based on nanostructures to administer drugs by the oral cavity, intended for buccal, sublingual, gastric or intestinal absorption. We analyzed published NP-in-matrix systems and compared main formulation characteristics, pharmacokinetics, release profiles and physicochemical stability improvements. The reported formulations are mainly semisolid or solid polymers, with polymeric or lipid nanoparticles and one active pharmaceutical ingredient. Regarding drug specifics, most of them are poorly permeable or greatly metabolized. The few studies with pharmacokinetics showed increased drug bioavailability and, sometimes, a controlled release rate. From our knowledge, the gathered data make up the first focused review of these trendy systems, which we believe will help to gain scientific deepness and future advancements in the field.

1 October 2019 in Journal of Drug Targeting
Verified
Journal Article
Closed access
DGDanilo Costa Geraldes
Danilo Costa Geraldes
VAViviane Lucia Beraldo de Araujo
Viviane Lucia Beraldo de Araujo
BPBoris Odelion Pichihua Pardo
Boris Odelion Pichihua Pardo
Adalberto Pessoa-JrAdalberto Pessoa-Jr
Adalberto Pessoa-Jr
MSMarco Antônio Stephano
Marco Antônio Stephano
LOLaura Oliveira-Nascimento
Laura Oliveira-Nascimento
Protein drugs present specific challenges to the maintenance of long-term stability, which can be accomplished by altering parameters of obtention, purification, molecule structure and formulation. As we believe, commercial formulations are undervalued; therefore, this review focuses on screening, categorising and discussing all formulations of protein drugs approved and not withdrawn by regulatory agencies from United States, Canada and Europe until mid-2018. Peptides (<50 amino acids) were not included to allow a more precise evaluation of choices for larger molecules. We extracted data from the DrugBank database, cross-checked it with the FDA purple book and supplemented it with patient information leaflets and papers. We further classified and discussed the entries according to protein function, drug delivery, route of administration and types of excipient (freeze-dried forms). In addition, alternative choices of excipients were discussed. Experimental work included here relates to targeting strategies with verified pharmacokinetics or in vivo effectiveness to identify physiologically relevant options. Although no single rule can be set for efficient protein formulation, our data help to better understand and optimise the choice for excipients and pharmaceutical dosage forms. For more information, see the Supplemental Data.

2 February 2023 in Molecules
Verified
Journal Article
Open access
PDF file
JAJanaina Ataide
Janaina Ataide
JCJulia Cedran Coco
Julia Cedran Coco
Érica Mendes dos SantosÉrica Mendes dos Santos
Érica Mendes dos Santos
VAViviane Lucia Beraldo de Araujo
Viviane Lucia Beraldo de Araujo
JSJéssica Ribeiro Alves Silva
Jéssica Ribeiro Alves Silva
PRISCILA MAZZOLAPRISCILA MAZZOLA
PRISCILA MAZZOLA
Achieving the best possible outcome for the therapy is the main goal of a medicine. Therefore, nanocarriers and co-delivery strategies were invented to meet this need, as they can benefit many diseases. This approach was applied specifically for cancer treatment, with some success. However, these strategies may benefit many other clinical issues. Skin is the largest and most exposed organ of the human body, with physiological and psychological properties. Due to its exposition and importance, it is not difficult to understand how many skin diseases may impact on patients’ lives, representing an important burden for society. Thus, this review aims to summarize the state of the art in research concerning nanocarriers and co-delivery strategies for topical agents’ applications targeting skin diseases. The challenge for the medicine of the future is to deliver the drug with spatial and temporal control. Therefore, the co-encapsulation of drugs and the appropriate form of administration for them are so important and remain as unmet needs.

13 September 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
VAViviane Lucia Beraldo de Araujo
Viviane Lucia Beraldo de Araujo
AVAna Flávia Siqueira Vicente
Ana Flávia Siqueira Vicente
MLMarcelo van Vliet Lima
Marcelo van Vliet Lima
AUAnita Umerska
Anita Umerska
Eliana B. SoutoEliana B. Souto
Eliana B. Souto
LOLaura Oliveira-Nascimento
Laura Oliveira-Nascimento
The first step of a successful nanoformulation development is preformulation studies, in which the best excipients, drug-excipient compatibility and interactions can be identified. During the formulation, the critical process parameters and their impact must be studied to establish the stable system with a high drug entrapment efficiency (EE). This work followed these steps to develop nanostructured lipid carriers (NLCs) to deliver the antibiotic levofloxacin (LV). The preformulation studies covered drug solubility in excipients and thorough characterization using thermal analysis, X-ray diffraction and spectroscopy. A design of experiment based on the process parameters identified nanoparticles with < 200 nm in size, polydispersity <= 0.3, zeta potential -21 to -24 mV, high EE formulations (>71 %) and an acceptable level of LV degradation products (0.37-1.13 %). To the best of our knowledge, this is the first time that a drug degradation is reported and studied in work on nanostructured lipids. LV impurities following the NLC production were detected, mainly levofloxacin N-oxide, a degradation product that has no antimicrobial activity and could interfere with LV quantification in spectrophotometric experiments. Also, the achievement of the highest EE in lipid nanoparticles than those described in the literature to date and the apparent protective action of NLC of entrapped-LV against degradation are important findings.

24 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VAViviane Lucia Beraldo de Araujo
Viviane Lucia Beraldo de Araujo
ABAnderson Beraldo-De-Araújo
Anderson Beraldo-De-Araújo
Juliana Souza Ribeiro CostaJuliana Souza Ribeiro Costa
Juliana Souza Ribeiro Costa
APAna Carolina Martins Pelegrine
Ana Carolina Martins Pelegrine
LRLígia Nunes Moraes Ribeiro
Lígia Nunes Moraes Ribeiro
LOLaura Oliveira-Nascimento
Laura Oliveira-Nascimento
Excipient interaction has become essential knowledge for rational formulation design of nanoparticles. Nanostructured lipid carriers (NLCs) include at least three types of excipient, which enhance excipient interaction possibilities and relevance. The present article introduces an alternative approach for evaluating a great number of excipients with few samples, using NLC as a model delivery system. This approach is based on two sequential experiments using Hall-2 experimental design and analysis of excipient interactions in respect to their physicochemical properties by multilevel statistics. NLCs were prepared using a hot emulsification-ultrasonication method with lidocaine and nine excipients (solid lipids, oils and surfactants). The evaluated parameters were z-average size (DLS), dispersity (DLS), zeta potential (electrophoretic mobility) and entrapment efficiency (HPLC). Cetyl palmitate, beeswax, castor oil, capric/caprylic acid and polysorbate 80 all presented larger effects amongst the studied factors as well as a clear pattern of synergistic interactions. Following the verified trends, we produced an optimized NLC that exhibited all desirable physicochemical characteristics and a modified drug release profile. Our results demonstrate the methodology’s robustness, which can be applied to other nanoparticles and establish a cost-effective excipient evaluation.

1 June 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VCVânia Carneiro
Vânia Carneiro
DTDaniela Barretto Barbosa Trivella
Daniela Barretto Barbosa Trivella
VSValéria Scorsato
Valéria Scorsato
VAViviane Lucia Beraldo de Araujo
Viviane Lucia Beraldo de Araujo
MDMariana P. Dias
Mariana P. Dias
RPRonaldo Pilli
Ronaldo Pilli